Cencora shares dropped 4.2% in afternoon trading following the company’s disclosure that certain Walgreens business that had been managed outside its prime vendor agreement has started to migrate to competing distributors as of July 1, 2026. The admission unsettled investors who view Walgreens as a stable, material customer for Cencora, although the company emphasized that its central prime vendor agreement with Walgreens - which comprises the bulk of that relationship - is unchanged.
Executives moved quickly to calm markets by restating Cencora’s full-year fiscal 2026 adjusted diluted earnings-per-share guidance in a range of $17.75 to $17.95. Management also said the reallocation of the off-agreement Walgreens volume was expected and had been accounted for in the company’s fourth-quarter commentary issued on August 5.
On the analyst front, Wells Fargo raised its price target on Cencora (COR) to $395 from $331 the previous day while keeping an Overweight rating, offering a partial counterweight to the negative market reaction. Still, that upgrade did not prevent selling pressure. Compounding investor concern was outgoing chief financial officer James Cleary’s previously revealed plan to sell roughly 20,000 shares, a disclosure that added an extra element of caution for some shareholders.
The broader market provided little justification for the decline: the S&P 500 was higher by 0.3% and the Nasdaq gained 0.6% during the session. That divergence underscores that the move was driven by company-specific developments rather than wider macroeconomic or sector-wide dynamics. Peers in pharmaceutical distribution, including Cardinal Health and McKesson, were not reported to have released material news the same day, indicating the selling pressure was concentrated in Cencora rather than reflecting a group-wide retreat.
Taken together, the confirmed loss of some customer volume, remaining questions about the total scope of the Walgreens relationship, and the disclosure of insider selling intentions outweighed the company’s reaffirmed EPS guidance and the favorable analyst update. Cencora shares touched a session low of $315.13, trading significantly below their 52-week high of $377.54 as the market adjusted expectations for the company’s near-term revenue profile.
Key context:
- Disclosure date: company confirmed volume shift effective July 1, 2026.
- Fiscal 2026 adjusted diluted EPS guidance reaffirmed at $17.75 to $17.95.
- Analyst activity: Wells Fargo raised COR price target to $395 from $331, maintaining an Overweight rating.
Investors weighing Cencora now balance the company’s guidance and the analyst upgrade against tangible shifts in customer volume and insider selling disclosures. The market’s reaction reflects recalibration of short-term revenue expectations rather than a confirmed long-term deterioration of the broader Walgreens relationship, per the company’s statements.